Indolizine compounds, preparation method and use thereof

An indolizine compound represented by formula I, a pharmaceutically acceptable salt, an enantiomer, a diastereomer, a tautomer, a solvate, a polymorph or a prodrug thereof,

• wherein,
• R1 is selected from the group consisting of
• R10 is selected from the group consisting of H, halogen, —NH2, —NO2, optionally substituted C1-C6 alkyl and optionally substituted C1-C4 alkoxy;
• R2 is selected from the group consisting of H, halogen, cyano and optionally substituted C1-C6 alkyl;
• R3 is
• R6 and R6□ are each independently selected from the group consisting of H, methyl, ethyl, propyl and cyclopropyl, and at least one of R6 and R6□ is H;
• X is an optionally substituted saturated or unsaturated 4-7 membered cyclic hydrocarbyl group or an optionally substituted 4-7 membered saturated or unsaturated heterocyclic group, and the heterocyclic group contains 1-2 heteroatoms selected from O, N, S and P;
• R4 and R5 are independently selected from the group consisting of H, halogen, —COOH, —CN, optionally substituted C1-C6 alkyl, optionally substituted 6-16 membered aryl, optionally substituted 5-16 membered heteroaryl, optionally substituted 4-8 membered saturated or unsaturated cycloalkyl, optionally substituted 4-8 membered saturated or unsaturated heterocyclic group, optionally substituted C1-C6 alkylcarbonyl, optionally substituted —C(O)O—(C1-C6 alkyl), —C(O)(NRaRb), dihydroxyboryl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C1-C6 alkyl sulfonyl group, optionally substituted C1-C6 alkyl sulfoxide group and optionally substituted C1-C6 alkyl mercapto group;
• wherein, the heteroaryl or heterocyclic group contains 1-3 heteroatoms selected from N, O, S, P;
• wherein, Ra and Rb are each independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, optionally substituted 3-8 membered cycloalkyl, and optionally substituted 4-8 membered heterocyclic group, or Ra and Rb are connected together with N to form an optionally substituted 4-8 membered heterocyclic ring;
• wherein the heterocyclic ring contains 1-3 heteroatoms selected from N, O, S and P;
• R7 is selected from the group consisting of H and optionally substituted C1-C6 alkyl;
• R8 and R9 are each independently selected from the group consisting of hydrogen, deuterium and optionally substituted C1-C6 alkyl;
• the optionally substituted substituents in R2, R7, R8, R9, R10, Ra and Rb include one or more substituents selected from the group consisting of H, halogen, C1-C4 alkyl, C1-C4 haloalkyl, nitro, —OH, amino, methoxy and dimethylamino.